Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Net Income (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Net Income data on record, last reported at -$17.9 million in Q3 2025.

  • For Q3 2025, Net Income rose 2.94% year-over-year to -$17.9 million; the TTM value through Sep 2025 reached -$64.9 million, up 27.09%, while the annual FY2024 figure was -$79.3 million, 55.81% up from the prior year.
  • Net Income reached -$17.9 million in Q3 2025 per BTAI's latest filing, up from -$19.8 million in the prior quarter.
  • Across five years, Net Income topped out at -$13.5 million in Q1 2025 and bottomed at -$54.9 million in Q4 2022.
  • Average Net Income over 4 years is -$31.7 million, with a median of -$26.8 million recorded in 2024.
  • Peak YoY movement for Net Income: tumbled 65.92% in 2023, then surged 62.63% in 2024.
  • A 4-year view of Net Income shows it stood at -$54.9 million in 2022, then soared by 57.3% to -$23.4 million in 2023, then surged by 41.57% to -$13.7 million in 2024, then tumbled by 30.93% to -$17.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$17.9 million in Q3 2025, -$19.8 million in Q2 2025, and -$13.5 million in Q1 2025.